Panic, anxiety, and chronic dyspnea

Journal of Palliative Medicine

Volumn 8, Issue 2, 2005, Pages 453-459

  Periyakoil, Vyjeyanthi S ^a,b   Skultety, Karyn ^a   Sheikh, Javaid ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 13Q; CHROMOSOME DUPLICATION; DOCTOR PATIENT RELATION; DYSAUTONOMIA; FAMILY; GASTROESOPHAGEAL REFLUX; GROWTH RETARDATION; HEALTH CARE; HUMAN; HYPOFIBRINOGENEMIA; PALLIATIVE THERAPY; PATIENT ATTITUDE; STOMACH FUNDOPLICATION;

AGED; AGED, 80 AND OVER; DYSPNEA; HOSPICE CARE; HUMANS; MALE; PANIC DISORDER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS;

EID: 18844417960     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2005.8.453     Document Type: Article

References (55)

1. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, Appleby IL, Anderson S, Palij M, Davies SO, et al.Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 1985;42:709-719.
2. Liebowitz MR, Gorman JM, Fyer A, Dillon D, Levitt M, Klein DF. Possible mechanisms for lactate's induction of panic. Am J Psychiatry 1986;143:495-502.
3. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF: Measurement of lactate-induced panic and anxiety. Psychiatry Res 1987;20:97-105.
4. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books, 1983.
5. Yalom ID: Love's Executioner and Other Tales of Psychotherapy. Stanford, CA: Stanford Alumni Association, 1989, pg. 260.
6. Jackson KC, Lipman AG: Anxiety in palliative care patients. J Pharmacuet Care Pain Symptom Control 1999;7:23-35.
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
8. Lloyd-Williams M: Criterion validation of the Edinburgh Postnatal Depression Scale as a screening tool for depression in patients with advanced metastatic cancer. J Pain Symptom Manage 2000;20:259-265.
9. Lloyd-Williams M: An analysis of the validity of the Hospital anxiety and depression scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manage 2001;22:990-996.
10. Smith EM, Gomm SA, Dickens CM: Assessing the independent contribution to quality of life from anxiety and depression in patients with advanced cancer. Palliat Med 2003;17:509-513.
11. Jacobsen PB, Breitbart W: Psychosocial aspects of palliative care. Cancer Control J 1996;3:17-26.
12. Muers MF, Round CE: Palliation of symptoms in non-small cell lung cancer: A study by the Yorkshire Regional Cancer Organisation thoracic group. Thorax 1993;48:339-343.
13. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K: Dyspnea in cancer patients: Prevalence and associated factors. J Pain Symptom Manage 2001;21:95-102.
14. Field MJ, Cassel CK (eds): Approaching Death: Improving Care at the End of Life. Washington, D.C.: National Academy Press.
15. Weiss SC, Emanuel LL, Fairclough DL, Emanuel DJ: Understanding the experience of pain in terminally ill patients. Lancet 2001;357:1311-1315.
16. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevelance, characterstics and distress in a cancer population. Qual Life Res 1994;3:183-189.
17. American Thoracic Society. Standards of diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152: S77-S152.
18. Celli BR, Snider GL, Heffner J: Standards for the diagnosis and care of patients with COPD. Am J Respir Crit Care Med 1995;152:S78-S121.
19. Brenes GA: Anxiety and chronic obstructive pulmonary disease: Prevalence, impact, and treatment. Psychosomat Med 2003;65:963-970.
20. Yellowlees PM, Alpers JH, Bowden JJ, Biyant GD, Ruffin RE: Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust 1987;146:305-307.
21. Aydin IO, Ulusahin A: Depression, anxiety comorbidity, and disability in tuberculosis and chronic obstructive pulmonary disease patients: Applicability of GHQ-12. Gen Hosp Psychiatry 2001;23:77-83.
22. Kellner R, Samet J, Pathak D: Dyspnea, anxiety, and depression in chronic respiratory impairment. Gen Hosp Psychiatry 1992;14:20-28.
23. Wittchen HU, Zhao S, Kessler RC, Eaton WW: DSMIII-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:355-364.
24. Yohannes AM, Baldwin RC, Connolly MJ: Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: Prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000;15:1090-1096.
25. Moore MC, Zebb BJ: The catastrophic misinterpretation of physiological distress. Behav Res Ther 1999;37:1105-1118.
26. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
27. Zandbergen J, Bright M, Pols H, Fernandez I, de Loof C, Griez EJ: Higher lifetime prevalence of respiratory diseases in panic disorder? Am J Psychiatry 1991;148:1583-1585.
28. Dudgeon DJ, Lertzman M: Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998;16:P212-219.
29. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE: A systematic review of the use of opioids in the management of dyspnea. Thorax 2002;57:939-944.
30. Coyne PJ, Viswanathan R, Smith TJ: Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-160.
31. Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, Shima Y, Uchitomi Y: Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage October 2003;26:962-968.
32. Bredin M, Corner J, Krinshnasamy M, Plant H, Bailey C, A'Hern R: Multicenter randomized controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ 1999;318:901-904.
33. American Psychiatric Association: Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998;155(suppl):1-34.
34. Mavissakalian MR, Michelson L, Dealy RS: Pharmacologic treatment of agora-phobia: Imipramine vs imipramine with programmed practice. Br J Psychiatry 1983;143:348-355.
35. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, Van Tuinen C: Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992;33:190-201.
36. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49.
37. Smoller JW, Pollack MH, Systrom D, Kradin RL: Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998;39:24-29.
38. Papp LA, Weiss JR, Greenberg HE, Rifkin A, Scharf SM, Gorman JM, Klein DF: Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. Am J Psychiatry 1995;152:1531.
39. Lecrubier Y, Bakker A, Dunbar G, Judge R: (1997a). A comparison of paroxetine, clomiparamine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica 1997;95:145-152.
40. Lecrubier Y, Judge R: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica 1997;95:153-160.
41. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C: Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998;173:54-60.
42. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998;155:1570-1577.
43. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379.
44. Pohl RB, Wolkow RM, Clary CM: Sertraline in the treatment of panic disorder: a double-blind multi-center trial. Am J Psychiatry 1998;155:1189-1195.
45. Pollack MH, Otto MW, Worthington JJ et al: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016.
46. Sandmann J, Lorch B, Bandelow B et al: Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatr 1998;31:117-121.
47. Versiani M, Cassano G, Perugi G, et al: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37.
48. Pollack MH, Worthington JJ, Otto MW et al: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-670.
49. Papp LA, Sinha SS, Martinez JM et al: Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998;34:207-209.
50. Pohl R, Yeragani VK, Balon R, Lycaki H: The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104.
51. Pollack MH, Simon NM, Worthington JJ et al: Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Clin Psychopharmacol 2003;17:276-282.
52. Smith BD, Salzman C: Do benzodiazepines cause depression? Hosp Commun Psychiatry 1991;42:1101-1102.
53. National Hospice and Palliative care Organization; Facts and Figures. 〈www.nhpco.org/files/public/Facts%20Figures%20Feb%2004.pdf〉 (Last accessed February 2004).
54. American Psychiatric Association: Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998;155(suppl):1-34.
55. Mavissakalian MR, Michelson L, Dealy RS. Pharmacologic treatment of agoraphobia: Imipramine vs imipramine with programmed practice. Br J Psychiatry 1983;143:348-355.